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Abstract
Background: In people with multiple sclerosis (MS) disabilities and limitations may negatively affect self-efficacy.
Lowered self-efficacy has been associated with decreases in health-related quality of life, physical activity and
cognitive performance. In an explorative observational study we found that a 3-day intensive social cognitive
program (Can Do Treatment [CDT]) with the participation of support partners was followed by substantial increases
in self-efficacy control and health-related quality of life 6 months after treatment in those people with MS who had
relapsing remitting disease and low disability.
Methods/Design: CDT is a sociologically oriented approach, its goal is to uncover and promote existing
capabilities, and the notion “stressor” is the central concept. CDT’s components are plenary group sessions, small
group sessions, consultations, a theatre evening, and start of the day with a joint activity. The small group sessions
form the actual training. Depending on their individual goals the participants join the training groups ‘Body’,
‘Feeling’ or ‘Life’, to work out their aims and to reduce their stressors. The multidisciplinary team includes a
psychiatrist, psychiatric nurse, neurologist, specialized MS nurse, physiotherapist, dance therapist, and a person with
MS. To evaluate the (cost)effectiveness of CDT in persons with relapsing remitting MS and low disability we perform
a single-centre, randomized controlled trial in 140 patients, with or without support partners. The primary outcome
is self-efficacy control. The secondary outcomes are self-efficacy function, health-related quality of life, autonomy
and participation, anxiety, depression, cost effectiveness and cost utility. The tertiary outcome is care-related strain
to support partners. Outcomes are assessed at baseline and at 1, 3 and 6 months after CDT.
Discussion: This randomized controlled trial will adequately evaluate the clinical and cost effectiveness of a 3-day
intensive social cognitive program in people with relapsing remitting MS and low disability, with self-efficacy
control as primary outcome.
Dutch trial registry: Application number: 22444
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Background
Multiple sclerosis (MS) is a chronic disease of the cen-
tral nervous system pathologically characterized by
immune-mediated inflammation, demyelination and
axonal degeneration. In most people with MS the first
symptoms occur between 20 and 45 years of age, and
the initial course is characterized by relapses that are
followed by complete or incomplete recovery: relapsing-
remitting MS (RRMS) [1]. The nature and intensity of
symptoms and disabilities are variable and largely un-
predictable. MS cannot be cured and despite the use of
disease modifying drugs most persons with RRMS pro-
gress to the secondary progressive phase (SPMS), for
which no treatment is available. Moreover, the response
to disease modifying treatment in RRMS varies between
persons and is difficult to predict.
Self-efficacy is a psychological concept that refers to
the degree in which a person is confident to complete
tasks and reach goals in specific situations [2]. It is a
core component in social cognitive theory, according to
which psychosocial functioning is determined by recip-
rocal interactions between personal factors, behavior
and the environment [3, 4]. In persons with MS disabil-
ities negatively affect independence, and the negative ex-
perience of decreasing independence may result in a
decrease in self-efficacy. Low self-efficacy is associated
with lower health-related quality of life (HRQoL) [5, 6],
less psychological adjustment [7], impaired cognition [8,
9] and less physical activity [6]. Moreover, a lowered
self-efficacy may cause patients to underestimate their
actual potential, as a result of which capabilities that are
still present may eventually disappear. Support partners
have also to deal with patients’ disabilities and loss of
self-efficacy. A more intensive appeal to them often re-
sults in an increased mental and physical strain and may
eventually weigh on the relation.
A wellness program is a structured intervention fo-
cused on achieving wellness in the physical, psycho-
logical and spiritual realm [10]. In the U.S.A. the Can
Do Program is a concentrated 4-day interdisciplinary
educational wellness program for MS patients, that pro-
motes health seeking behaviors, lifestyle empowerment
and exercise [11]. The program aims to enable patients
the uncovering of existing capabilities [11], and an im-
provement in self-efficacy and perceived health has in-
deed been observed in patients who took part in this
program [11].
In an explorative observational study we assessed in
MS patients the effect of an intense, multidisciplinary, 3-
day, social cognitive wellness program (Can Do Treat-
ment [CDT]) with the participation of support partners
[12]. It was found that in the RRMS group 6 months
after the intervention the self-efficacy control had signifi-
cantly increased by 25.8 %, the mental HRQoL by 22.3 %
and the physical HRQoL by 17.6 %. Moreover, in the
low disability (Expanded Disability Status Scale [EDSS]
score <4.0) group the increase in self-efficacy control at
6 months was 23.8 % and the mental HRQoL 19.3 %.
Aims and objectives
The overall aim of the study is to evaluate in a random-
ized controlled trial the clinical and cost effectiveness of
CDT, with or without the participation of support part-
ners, in comparison to no such treatment for people
with RRMS and low disability.
The primary objective is to evaluate the effectiveness
of CDT compared to no such treatment in increasing
self-efficacy control (primary outcome) during 6 months
after treatment.
The secondary objectives are to evaluate:
1) the effectiveness of CDT compared to no such
treatment in increasing self-efficacy function,
autonomy and participation, HRQoL and coping
during 6 months after treatment;
2) the effectiveness of CDT compared to no such
treatment in decreasing anxiety and depression
during 6 months after treatment;
3) the cost effectiveness and cost utility of CDT during
6 months after treatment;
The tertiary objective is to evaluate the effectiveness of
CDT compared to no such treatment in decreasing care-
related strain in support partners during 6 months after
treatment.
Methods/Design
Study design and organization
The study is a single-centre, parallel group, randomized,
controlled trial to evaluate the clinical and cost ef-
fectiveness of CDT, with or without support partners,
in increasing self-efficacy control in RRMS patients
with low disability. The 3-day CDT is given to groups of
20 persons in Zorghotel Spelderholt, Beekbergen, The
Netherlands, a facility especially equipped for the accom-
modation of people with impaired health. The first group
was treated in April 2013. The ratio between the numbers
of patients with support partner and without support part-
ners is about 3:4. The CDTs are given from Friday to
Sunday.
The control groups receive no CDT and may receive
any care or treatments that are deemed necessary by the
treating neurologists, MS nurses or other caregivers
(‘care as usual’). In the experimental groups and the par-
allel control groups the baseline assessment is one week
before the CDT, and in all groups the duration of
follow-up is 6 months with assessments being performed
at 1, 3 and 6 months.
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The underlying idea of a 3-day social cognitive inter-
vention program was conceived by the National MS
Foundation The Netherlands, Rotterdam, The Netherlands
(AvdZ), and further developed in collaboration with
PsyToBe (RR, LD) and the other team members. The
study is initiated, financed and conducted by the National
MS Foundation The Netherlands, and the CDTs are orga-
nized and managed by this foundation (MvD). The contri-
butions of the psychiatrist and the psychiatric nurse are
part of regular care and are covered by the health insur-
ance. The MS4 Research Institute is responsible for the
scientific evaluations.
The study is ongoing (recruiting patients).
Can do treatment
Concept
The goal of CDT is to uncover and promote existing
capabilities, with the notion “stressor” as central con-
cept. It is primarily a sociologically oriented approach, as
it tries to identify stressors that confine patients with
MS to their physical, psychological or social roles. To re-
duce these stressors, CDT is based on the following
principles: identification and reduction of existing
stressors; client-centeredness; inclusion of support part-
ner (partner or a significant informal caregiver); group
sessions; and self-reliance, autonomy, and acceptance as
central themes. Accordingly, CDT focuses on the explor-
ation of stressors that confine patients to their disease
and their limitations; reduces the relevant stressors; ex-
plores and pushes personal boundaries; and establishes
new personal boundaries by making optimal use of the
existing potential. To place the individual capabilities in
a realistic framework, CDT’s central mottos are ‘Can’,
‘Will’, ‘Choose’, ‘Open up to others’, and ‘Do’. CDT’s mes-
sages are that by exploring their boundaries patients be-
come more aware of their faculties and that the resulting
self-management leads to higher awareness of potentials
and a better communication with care professionals.
Components
The CDT’s components are large group sessions, small
group sessions, consultations (carrousel), a theatre even-
ing, and start of the day with a joint activity (optionally).
In the plenary group sessions participants make opti-
mal use of their existing potentials, learn how to support
and encourage other participants, and experiment how
to give the required feedback to the multidisciplinary
team; in group sessions in which half of the participants
take part stressors are identified that have to be ad-
dressed most, and realizable individual aims (one or
two) are formulated.
The small group sessions form the actual training. De-
pending on their individual goals the participants sign
up for the training groups ‘Body’, ‘Feeling’ or ‘Life’, to
work out their aims and to experiment whether they can
reduce their stressors. The Body sessions focus on the
exploration of the physical capabilities and are coached
by a physiotherapist. The Feeling sessions focus on the
exploration of the emotional potential and are coached
by a psychiatrist and a psychiatric nurse. The Life ses-
sions focus on the exploration of capabilities relating to
the daily living with MS and are coached by a neurolo-
gist, a registered nurse specialized in MS and a person
with MS. In addition, there are relaxation sessions for
those who have difficulties to experience their body: the
Dance session focuses on body experience and relax-
ation, and makes participants aware of the relationship
between physical sensations and their emotions and feel-
ings, whereas the Physical session focuses on relaxation
through physical strain. The choices between the various
small group sessions are made independently by the in-
dividual participants themselves.
After having identified and formulated in the large
group sessions their individual stressors and aims, the
participants sign in for one or more group consultations,
during which they verify whether their aims are
realizable by asking the members of the multidisciplinary
team for aim-related medical information.
On the informal theater evening the participants prac-
tice to change roles and to show their potentials by
openly experimenting. They do their best to perform be-
fore each other and the team. The jointly created even-
ing performance increases the cohesion within the group
and learns participants to find an equilibrium between
consuming and action.
During an optional joint activity (walk in the woods)
at the start of the day the participants experiment with
physical challenges and with the management of their
energy.
Multidisciplinary team
The multidisciplinary team includes a psychiatrist, psy-
chiatric nurse, neurologist, specialized MS nurse, physio-
therapist, dance therapist, and a person with MS. The
team members respect and understand the participants’
individual qualities and differences, and they stimulate,
defy and confront them to explore and push their
boundaries. Apart from the consultations, the team
keeps to coaching, stimulating and activating the partici-
pants. By participating in all large group sessions the
team members become acquainted with the individual
stressors and goals. During the consultations they have a
professional and informative role. In the small group
sessions every discipline focuses on its own area of inter-
est. During a tip time at the end of each day the team
members evaluate the sessions, inform each other on the
participants’ progresses and obstacles, discuss whether
the participants make optimal use of the opportunities,
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and monitor to what extent the personal goals are being
attained.
Eligibility criteria
The eligibility criteria for persons with MS are 1) diag-
nosis RRMS, 2) being diagnosed at least one year ago,3)
EDSS score 4.0 or lower, 4) no symptoms suggestive of a
relapse, 5) no relapse in the preceding 4 weeks, 6) will-
ing and capable to participate in the investigations, 7)
having access to the internet, and 8) having given in-
formed consent.
The eligibility criteria for the support partners are 1)
willing and capable to participate in the investigations,
2) having access to the internet, and 3) having given in-
formed consent.
Recruitment and inclusion
Participants are recruited by the National MS Foundation
The Netherlands via publications in their quarterly journal
Nieuwslijn, postings on the website www.nationaalms-
fonds.nl, information on the website of the organisation’s
National MS Network (a portal for MS caregivers), infor-
mation on social media (facebook, twitter, hyves), and pre-
sentations during meetings of neurologists, MS nurses
and other caregivers. Persons who are interested are re-
quested to contact the National MS Foundation The
Netherlands by phone (+105919839) in order to be in-
formed about the various aspects of the CDT and of the
study, like objectives and design. If they wish to receive
further information, the patient information leaflet and
consent form are sent to them by regular mail, and a sec-
ond phone call is scheduled with an interval of at least
one week. During the second contact by phone, the study
assistant (AH) checks the eligibility criteria. If the patient
meets the criteria, eventual questions are answered. Per-
sons are explicitly informed that participants in the con-
trol group have the right to receive the CDT after their
study participation has ended. Questions regarding the
content of the CDT treatment are answered by phone by
the MS nurse (MH) of the study team or by the principal
investigator (PJJ). After another reflection period of at
least one week, the MS nurse (MH) contacts the person
and if he/she is willing to participate the inclusion proced-
ure follows, during which by use of predefined questions
the disease course (RRMS) is verified and the disability
(EDSS 4.0 or less) is assessed (see below).
Ethical and privacy aspects
There are no financial incentives to participate. The ex-
pected advantages of study participation are the chances
of a clinically relevant increase in self-efficacy and in
HRQoL about 6 months after treatment. The disadvan-
tages include the intensive character of the CDT, the
completion of questionnaires 4 times over a 6 months
period, taking about 45 minutes per time, and the 50 %
chance of being randomized into the control group. The
risks include the possible occurrence of negative emo-
tional moments, negative effect of the confrontation
with one’s symptoms, disabilities and limitations, and acci-
dents during the physical training sessions or joint activity.
The CDT constitutes an unusual mental and physical
pressure and might therefore lead to the temporary occur-
rence or worsening of MS symptoms, like fatigue, mood
alteration, or emotions. The continuous presence of the
experienced team guarantees that unwanted changes are
rapidly noticed and adequately cared for.
The study data are coded via an automatically generated
code of 10 digits. The identity of the participants is not
disclosed in publications or study reports. The protocol
has been reviewed and approved by the ethical committee
Medisch Ethische Toetsing Onderzoek Patiënten en Proef-
personen in Tilburg, The Netherlands. Medische Ethische
Toetsing Commissie (METC) number: M499. NL number:
NL4220502812. The study is being performed in agree-
ment with the Declaration of Helsinki (Ethical Principles
for Medical Research involving Human Subjects version
2013; 64th World Medical Association General Assembly,
Fortaleza, Brazil, October 2013) (www.wma.net) and the
Wet medisch-wetenschappelijk onderzoek met mensen
(www.wetten.overheid.nl/BWBR0009408). Patients are
informed that they have the right to discontinue their
participation or withdraw their consent at any time and
are not obliged to state their reasons. The completion of
the questionnaires takes about 45 minutes per sched-
uled assessment (baseline and at 1, 3 and 6 months) and
the assessment of the EDSS by phone takes about 10 to
20 minutes (see below).
Data acquisition
The data acquisition is web-based. Patients complete the
informed consent form online and start participation by
sending their confirmation. After having received a per-
sonal code they log on to the website of the MS4 Re-
search Institute (www.ms4ri.nl) and choose a username
and password. The study is performed using the Lime-
Survey software, an open source online application.
There was no testing of the MS4 Research Institute’s
platform for this study since it was already being used in
various research projects. The items of the question-
naires are fixed and the responses are automatically cap-
tured. To protect the personal data from unauthorized
access various mechanisms are used to comply with
European Union regulations concerning online medical
data, including the use of a personal username and a
strong password, separation in the database of personal
information from the answers to the questions, each
screen having a username and password protection, Vir-
tual Private Network tunnelling, 256-bits encryption,
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and the encryption of the participants’ identities via
unique 10 digits codes. Automated completeness checks
are done before questionnaires can be submitted. The par-
ticipants see an overview of all questions and answers be-
fore submission and they can change the answers before
submitting. After submission changes are no longer
possible. The help desk (MH) contacts participants by
phone in case they do not succeed in completing
questionnaires.
Primary outcome measure
Self-efficacy control is assessed by the Multiple Sclerosis
Self-Efficacy Scale (MSSES). The MSSES is an 18-item,
psychometrically validated, self-report questionnaire for
the assessment of self-efficacy [13]. The MSSES consists
of two 9-item subscales of Function and Control. Each
item is scored on a Likert-like scale form 10 (very uncer-
tain) to 100 (very certain) and addition of the respective
item scores yields the MSSES-Function score and the
MSSES-Control score, both ranging from 90 (minimum)
to 900 (maximum). The MSSES-Function subscale
measures confidence with functional abilities, whereas
the MSSES-Control subscale measures confidence with
managing symptoms and coping with the demands of
illness [13].
Secondary outcome measures
Self-efficacy function is assessed with the MSSES
(see above).
Participation and autonomy is assessed with the Im-
pact on Participation and Autonomy (IPA) question-
naire, a 32-item, psychometrically validated, generic,
self-report instrument for the quantification of limitations
in participation and autonomy in people with chronic
health conditions [14, 15]. The IPA-Limitations subscale
assesses perceived limitations in participation and au-
tonomy in relation to 32 different life situations across
five subscales: autonomy indoors, family role, autonomy
outdoors, social life and relationships, and work and
education [14–16]. Items are rated on a 5-point scale
from 0 (very good) to 4 (very poor), and a higher score
indicates a higher limitation to participation and auton-
omy. The IPA-Problems subscale examines the extent
to which these limitations are experienced as problem-
atic, by assessing nine different areas of participation
and autonomy: mobility, self care, activities in and
around the house, looking after money, leisure, social
life and relationships, paid or voluntary work, education
and training, and helping and supporting other people
[14–16]. The perceived problems are graded on a 3-
point scale ranging from 0 (no problem) to 2 (severe
problems), and a higher IPA-Problems score indicates a
greater experience of problems [14–16].
HRQoL is assessed by the Multiple Sclerosis Quality
of Life 54-Items (MSQoL-54) and the EuroQoL-5
Dimensions-5 Levels (EQ-5D-5L) questionnaires.
The MSQoL-54 is a psychometrically validated, MS-
specific, multi-dimensional inventory of patient-centered
health status, and consists of the Short Form 36-Items
health survey as a generic core measure, supplemented
with 18 questions on items relevant to patients with MS
in the areas of health distress, sexual function, satisfac-
tion with sexual function, overall quality of life, cognitive
function, energy, and pain and social function [17]. The
MSQoL-54 contains 52 items distributed into 12 scales,
and two single items. A physical and a mental dimension
underlie the MSQoL-54: the Physical and Mental do-
mains [17]. Scores for each domain range from 0 to 100,
where higher values indicate better HRQoL.
The EQ-5D-5L is a generic, preference-based, self-
reported HRQoL instrument that was developed by the
EuroQol Group to measure decrements in health [18, 19].
Respondents record their level of problems experienced in
five domains of health: mobility, self-care, usual activities,
pain or discomfort, and anxiety or depression, indicating
whether they are having no problems or slight, moderate,
severe or extreme problems in each assessed domain.
Based on the combination of responses, respondents are
classified into one of 3125 unique EQ-5D-5L health-state
profiles. Each health state is converted to a single utility
value representing general population preferences. Utility
is measured on a cardinal scale anchored at 1 (perfect
health) and 0 (absence of life/dead), and valuations less
than zero (as low as -0.594), reflecting health states ‘worse
than death’, can exist.
Coping styles are assessed with the Utrecht Coping
List (UCL) [20]. The UCL consists of 47 items, measuring
7 independent subscales: active problem solving, palliative
reaction, avoidance and passive expectancy, seeking social
support, passive reaction pattern, expressing emotions,
and comforting cognitions [20, 21]. Active problem solv-
ing and comforting cognitions are thought to represent
active coping styles, while avoidance, passive reaction and
expressing emotions are thought to reflect more passive
coping styles. Palliative reaction and seeking social support
are related to both active and passive coping styles. The
scores on the subscales palliative reaction and avoidance
range from 8 to 32, and scores on the subscales active
problem solving and passive reaction range between 7 and
28. Scores on subscales emotion expression, comforting
cognitions and social support can range from 3 to 12, 5 to
20 and from 6 to 24 respectively.
Anxiety and depression are measured by the Hospital
Anxiety and Depression Scale (HADS), a psychometric-
ally validated, 14-item, self-report questionnaire for anx-
iety and depression [22]. The HADS consists of two
subscales, one for anxiety and one for depression, each
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comprising seven questions. Each question scores 0 to 3
points, and a total subscale score of 0 to 7 points indi-
cate no anxiety/depression, 8 to 10 points indicate pos-
sible mild to moderate symptoms of anxiety/depression,
and 11 to 21 points indicate a probable clinically signifi-
cant condition of anxiety/depression [22].
Tertiary outcome measure
The care-related strain to support partners is measured
with the Caregiver Strain Index (CSI). The CSI is a
caregiver-specific measure that asks whether aspects of
the caregivers’ lives, such as sleep, finances and normal
routine have been affected by their caring role, and
whether this has placed a physical and mental strain
upon them [23, 24]. The CSI includes thirteen items that
are scored with Yes (1) or No (0) yielding a total score
between 0 and 13. A higher score indicates higher care-
related strain, and caregivers' self-reports of experiencing
situations that conflict with giving help are associated
with CSI scores of 7 or higher [21].
Other baseline data
Disability is measured by use of the EDSS.The EDSS is
based on a neurological examination that provides the
basis for the assessment of several functional systems
that, according to predefined algorithms, contribute to
the EDSS score [25].
Statistical aspects
Based on the differences in MSSES control scores be-
tween baseline and at 6 months after CDT found in
RRMS patients with EDSS score <4.0 in the explorative
observational study [12], we conducted the following
power analysis. We assume at 6 months an average of
650 for the experimental group and an average of 560
for the control group (an increase of 10 points compared
to the baseline average found in the observational study).
Assuming an SD of 200 on the 6 months measurement
we would need 79 patients per group in order to obtain
a power of 80 %, when using a two-sided t-test with an
alpha of 5 %. However as we will use the baseline meas-
urement in the analysis this number has to be multiplied
by a design factor equalling 1 – r2baseline, 6 months. Assum-
ing a correlation of 0.5 (also based on the observational
data) this design factor equals 0.75. Therefore, the num-
ber of analyzable patients needed to obtain a power of
80 % equals approximately 60 per condition. Taking ac-
count of an expected drop-out of 15 %, we will include a
total of 140 patients; approximately 60 with support
partner and 80 without support partner.
The randomisation is performed by a statistician who
is not otherwise associated with the study (Petra Koop-
mans PhD, Signidat, Groningen, The Netherlands) via a
stratified block randomisation with disease duration and
gender as blocking factors. The randomisation list was
made at the Department for Health Evidence (RD),
Radboud university medical center, Nijmegen, The
Netherlands.
The primary outcome variable is the MSSES control
score after 6 months. This will be analysed using an
ANCOVA with the assessment of 6 months as
dependent variable and condition and baseline assess-
ment as independent variables For all other variables the
6 months values will be analysed in a similar way. All
analyses will be performed according to the intention-
to-treat principle. The statistical analyses will be per-
formed at the Department for Health Evidence, Radboud
university medical center, Nijmegen, The Netherlands.
Economic evaluation
The economic evaluation is a combination of a cost ef-
fectiveness analysis (CEA) and cost utility analysis
(CUA). In addition to the effect assessments the follow-
ing instruments will be used: 1) a questionnaire on care
use and participation, to gain insight in the costs for
health care, the patient and his environment, and the
costs outside the health care, 2) the EQ-5D-5L to gain
insight into the generic quality of life and utilities. Both
instruments are applied simultaneously with the out-
comes measures of the effect study. To translate care
use and participation in costs, the Dutch Manual for
Costing in Economic Evaluations (Nederlandse Handle-
iding voor Kostenonderzoek) will be used [26]. The pri-
mary outcome measure for the CEA will be the MSSES
control score at 6 months, and the primary outcome
measure for the CUA will be the Quality Adjusted Life
Years (QALYs). The QALY is a measure in which the
number of life years is multiplied with a correction fac-
tor the quality of those life years, also called utility. The
utilities will be calculated by means of the Dutch tariff
that is actually being developed for the EQ-5D-5L.
To enable a combined assessment of costs and ef-
fects the incremental cost effectiveness ratio (ICER)
will be calculated, according to the following for-
mula: ICER ¼ Costsintervention−Costscontrolð ÞEffectsintervention−Effectscontrolð Þ , wherein ‘Costs
intervention’ represents the costs during the whole
follow up period in the CDT group, ‘Costs control’
the costs during the whole follow up period in the
control group (‘care as usual’), ‘Effects intervention’
the effects at the end of the follow up period in the CDT
group, and ‘Effects control’ the effects at the end of the
follow up period in the control group. To test for eventual
uncertainties that may arise in an economic evaluation
study, sensitivity analyses will be performed to assess
whether different assumptions lead to different ICER out-
comes. To gain insight into sample uncertainty bootstrap
analysis will be performed. Based on the results of the
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bootstrap analysis the ICER uncertainty will be repre-
sented graphically. The probability that CDT is cost-
effective will be represented with a cost effectiveness ac-
ceptance curve.
Discussion
In an exploratory observational study we assessed in
people with MS the potential effectiveness and feasibility
of an intensive social-cognitive program with the partici-
pation of support partners and found that in the RRMS
subgroup self-efficacy control, mental HRQoL and phys-
ical HRQoL had increased by 24.8 %, 22.3 % and 17.6 %,
respectively. Likewise, in persons with low disability
(EDSS score 4.0 or less) the self-efficacy control and
mental HRQoL had increased with 23.8 % and 19.3 %,
respectively. No such changes were seen in the progres-
sive subgroup or in persons with higher disability
(EDSS > 4.0). Therefore, we conceived a randomized
controlled trial to further evaluate the (cost)effectiveness
of CDT in people with RRMS and low disability. Several
other observational studies showed beneficial effects of
various types of social-cognitive wellness programs in
MS [11, 27, 28], but as yet there are no reports of ran-
domized controlled trials [29].
We considered the MSSES control score the main out-
come measure, and not the MSSES function or total
score, because the pilot study showed an evident differ-
ence between the change in the self-efficacy control vs.
the absence of change in self-efficacy function (+1.2 %)
[12]. Conceptually, the control and functional subscales
of the MSSES measure different dimensions of self-
efficacy: the control subscale measures confidence with
managing symptoms and coping with the demands of ill-
ness, whereas the function subscale measures confidence
with functional abilities.
Having had a relapse in the preceding 4 weeks is an
exclusion criterion, since we considered that being in a
suboptimal condition due to clinical disease activity
would increase the risk of unwanted side effects, and
would also interfere with the efficacy of CDT. Partici-
pants with a relapse during the study period are not ex-
cluded from the study, as we do not expect that having
experienced a relapse in the 6 month study period or ex-
periencing a relapse at the month 6 assessment does
substantially affect self-efficacy; self-efficacy is consid-
ered a rather stable trait that requires an intense inter-
vention like CDT to be modified. To address this point
in the analysis phase, we assess the on-study occurrence
of relapses and will perform a stratified secondary ana-
lysis to assess an eventual effect of relapses on the pri-
mary outcome.
In an extension phase of 6 months duration we will
assess the effect of CDT in the longer term. After the
patients in the intervention arm of the study have
completed the study they are eligible to be followed for
another 6 months, and patients in the control arm have
the option to receive the CDT and are also eligible to be
followed for another 6 months. Thus, we will be able to
assess whether the effect of CDT is sustained on the lon-
ger term (12 months), and to assess whether in the control
group a similar change in self-efficacy control occurs after
CDT as in the RCT intervention group.
An important aspect of complex interventions is their
feasibility in real life, e.g. in terms of drop outs, logistics
and costs. The drop-out percentage during the 3-day
intervention in the pilot study was low (7.4 %) [12],
which suggests that the drop out in real life conditions
may be limited. As to logistics, in the RCT all CDTs are
given at one central location in The Netherlands, as was
the case in the pilot study. After the RCT the CDTs will
also be given at this location, which has been proven to
be easy accessible and well-equipped. Similar approaches
could be taken in other countries. A practical aspect of
CDT’s implementation and embedding in MS care are
the costs in relation to the clinical effects; to be able to
weigh the benefits against the costs we investigate the
cost-effectiveness of CDT.
Finally, it may be conceived that CDT is influenced by
specific aspects of the Dutch health care system and
could therefore be of less interest to people with MS
treated in other countries. It is of note that a comparable
treatment, the Can Do Program, is being given to people
with MS in the U.S.A. and improvement in self-efficacy
and perceived health was observed in patients who took
part in this program [11]. Moreover, none of the compo-
nents of CDT is related to specific aspects of the Dutch
health care system or the Dutch culture. Therefore, in
terms of content and effectiveness no relevant differ-
ences between countries are to be expected. Yet, the im-
plementation of the study results will depend on the
incorporation of CDT in the regular care process, which
may differ between countries given the differences in
health care systems and reimbursement policies.
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